Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

Friendly bacteria: do we really need to eat probiotic yogurts?

According to the World Health Organization (WHO) probiotics are “live microorganisms which when administered in adequate amounts confer a health benefit on the host”.

19 Sep 2012

Loss of normal microbial diversity may be culprit behind chronic sinusitis

A common bacteria ever-present on the human skin and previously considered harmless, may, in fact, be the culprit behind chronic sinusitis, a painful, recurring swelling of the sinuses that strikes more than one in ten Americans each year, according to a study by scientists at the University of California, San Francisco.

13 Sep 2012

BRI scientists receive two major grant awards for research into autoimmunity prevention

Benaroya Research Institute at Virginia Mason (BRI) recently received two major grant awards to explore how to regulate the immune system, as part of a nationwide collaborative program to prevent autoimmune diseases.

11 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.

5 Sep 2012

EC grants European market authorization for Revestive to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the European Commission has granted European market authorization for the medicinal product teduglutide (trade name in Europe: Revestive) as a once-daily treatment for adult patients with short bowel syndrome.

5 Sep 2012

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Soligenix, Inc., a development stage biopharmaceutical company, announced today the results of a Phase 1B clinical trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax, designed to improve the immunogenicity of the vaccine.

31 Aug 2012

Altheus Therapeutics initiates enrollment in Zoenasa Phase 2 study for ulcerative colitis

Altheus Therapeutics announced today it has randomized its first patient in a comparator-controlled Phase 2 efficacy study of Zoenasa, a novel combination therapy for ulcerative colitis (UC).

29 Aug 2012

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.

28 Aug 2012

MR enterography performs well in children with Crohn disease

Parents with children nine years old and older who have Crohn disease should ask their children's doctor about MR enterography as a replacement for small bowel x-rays or CT enterography, a new study indicates.

23 Aug 2012

VolitionRX to initiate NuQ blood-based tests in colorectal cancer clinical trial

VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces that its subsidiary Belgian Volition has signed an agreement with the Biobank of CHU UCL Mont-Godinne, an academic hospital in Yvoir, Belgium.

22 Aug 2012

FDA committee to review NPS’ Gattex NDA in October

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that its New Drug Application (NDA) for Gattex (teduglutide) will be discussed at the Gastrointestinal Drugs Advisory Committee meeting scheduled for October 16, 2012.

22 Aug 2012

HRT linked to ulcerative colitis in postmenopausal women

Taking postmenopausal hormone replacement therapy increases the risk for ulcerative colitis, but not Crohn’s disease, a study shows.

17 Aug 2012

PKS-positive E. coli may encourage development of colon cancer

Scientists at the University of Liverpool have identified a type of E. coli bacteria that may encourage the development of colon cancer.

17 Aug 2012

CD4 T cells orchestrate inflammatory attack on the artery wall

Most people probably know that heart disease remains the nation's No. 1 killer. But what many may be surprised to learn is that cholesterol has a major accomplice in causing dangerous arterial plaque buildup that can trigger a heart attack. The culprit? Inflammatory cells produced by the immune system.

15 Aug 2012

FDA extends PDUFA action date for NPS Gattex NDA

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that it has received a communication from the U.S. Food and Drug Administration extending the Prescription Drug User Fee Act action date for its New Drug Application for Gattex (teduglutide) by three months to December 30, 2012.

13 Aug 2012

Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

Meritage Pharma, Inc. announced that it has initiated a Phase 2 clinical trial to evaluate oral budesonide suspension (OBS) for the treatment of adolescents and young adults with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation.

13 Aug 2012

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.

9 Aug 2012

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).

9 Aug 2012